尖峰集团(600668.SH)：JFAN-1001甲磺酸盐胶囊获得药物临床试验批准通知书

Core Viewpoint - The company has received approval for a new anti-tumor drug, JFAN-1001, which targets a specific mutation in lung cancer [1] Group 1: Company Developments - Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Jianfeng Group, has received a clinical trial approval notice from the National Medical Products Administration [1] - The approval includes three notification numbers: 2025LP03024, 2025LP03025, and 2025LP03026 [1] Group 2: Product Information - JFAN-1001 mesylate capsules are developed as a new anti-tumor drug by Jianfeng Yien Biotechnology Co., Ltd., a holding subsidiary of Jianfeng [1] - The drug is classified as a Class 1 chemical drug and is indicated for locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-T790M secondary mutation [1]